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The body fluid homeostasis is essential for the normal life. In the maintenance of water 
balance, the most important factor and regulated process is the excretory function of the 
kidneys. The kidneys are capable to compensate not only the daily fluctuations of water intake 
but also the consequences of fluid loss (respiration, perspiration, sweating, hemorrhage). The 
final volume and osmolality of the excreted urine is set in the collecting duct via hormonal 
regulation. The hormone of water conservation is the vasopressin (AVP) and large volume of 
urine is produced and excreted in absence of AVP secretion or if AVP is ineffective in the 
kidneys. The aquaporin-2 water channel (AQP2) is expressed in the principal cells and it plays 
essential role in the reabsorption of water in the collecting ducts via type 2 vasopressin receptor 
(V2R) mediated mechanism. If neural or hormonal regulation fails to operate the normal 
function of AVP-V2R-AQP2 system, it can result in various diseases such as diabetes insipidus 
(DI) or nephrogenic syndrome of inappropriate diuresis (NSIAD). The DI is characterized by 
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excessive production of hyposmotic urine (“insipidus” means tasteless) due to the inability of 
the kidneys to concentrate urine. In this chapter, we focus and discuss the pathophysiology of 




The maintenance of constant volume and composition of the body fluids requires that 
the daily water intake and water loss are matched and tightly regulated. The balance between 
the water input and output is mainly regulated through the kidneys, although water intake is 
also controlled by thirst. The urine formation by the kidneys is the key regulatory factor in the 
maintenance of water and electrolyte homeostasis of the human body. The kidneys respond 
rapidly and appropriately to body fluid osmolality and volume fluctuations, however the 
kidneys are able to fulfill these homeostatic tasks only under hormonal and neural regulatory 
mechanisms. The glomerular filtration by the kidneys produce 120 ml of fluid in a minute and 
the tubular system allows great variations in the rate of final fluid excretion. The volume of 
urine production can be greatly varied in antidiuresis (water deprivation) and in water diuresis 
(after excessive fluid load). Normally, about 1% of the filtered water is finally excreted as urine; 
the average urine output is ~0.5-1.5 ml/minute. Some segments of the tubular system have 
permanent high water permeability because certain types of aquaporin water channels (AQP) 
reside constitutively on their apical and basolateral membranes. In contrary, other segments are 
virtually water impermeable due to the lack of aquaporin water channels in the plasma 
membrane compartments. In healthy humans approximately 85% of the filtered fluid is 
reabsorbed in the proximal tubule and in the loop of Henle, independently on the water 
homeostatic status of the body. Approximately 8-14.5% of the glomerular filtered fluid is 
reabsorbed in the collecting ducts and it is under tight hormonal control via vasopressin 
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(arginine-vasopressin in humans, AVP; also called as antidiuretic hormone, ADH) and atrial 
natriuretic peptide (ANP) actions (Robertson 2001; Saito 2010). The AVP is synthesized as 
prohormone which is later cleaved to nonapeptide AVP in the supraoptic and paraventricular 
nuclei of the hypothalamus (Fliers et al. 1985; Sklar and Schrier 1983). The produced AVP is 
transported by axonal transport via the supraopticohypophyseal into the neurohypophysis and 
secreted from here in response to stimulation. A very sensitive mechanism allows that even less 
than 1% increase in osmolality stimulates osmoreceptors in the hypothalamus, which in turn 
induce the release of AVP into the systemic circulation. The secreted AVP circulates in the 
blood and primarily acts in the kidneys via V2R.  In addition to the AVP production and 
secretion, higher increase in extracellular osmolality leads to thirst perception, which drives 
drinking behavior helping to restore the normal osmolality and volume of the fluid 
compartments in the body. The vascular effects (vasoconstriction and total peripheral resistance 
increase) of AVP due to type 1 vasopressin receptor (V1R) activation are manifested only at 
greatly elevated AVP levels. This huge increase in AVP production and secretion can be seen 
only in response to baroreceptor activation reflex when blood volume changes reach at least 5-
10%.  
The collecting tubules are divided into subsegments such as cortical, outer medullary, 
and inner medullary collecting ducts but in all subsegments the AVP regulates the reabsorption 
of water. (The water permeability of the tight junctions between the epithelial cells of the 
collecting tubule is negligible). The overall action of the AVP is the water conservation and 
formation of hyperosmotic urine. During antidiuresis, the AVP makes the luminal membrane 
of the principal cells in the collecting ducts water-permeable and water is passively reabsorbed 
via AQP channels due to the existing osmotic gradient between the tubular fluid and the 
hyperosmotic interstitium. The effect of AVP is induced by the binding to and activation of the 
basolaterally located V2R in the collecting ducts which is followed by consequent signaling 
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transduction steps leading to the translocation of AQP2 from endomembranes to the apical 
plasma membrane (Moeller et al. 2013). Under normal circumstances, the AQP2 is inserted in 
the luminal membrane of the principal cells as homotetrameric water channel.    
The AVP also regulates the urea permeability of the principal cells since its effect is 
required for the normal expression and function of urea transporters in the inner medullary 
collecting duct, enhancing the urea recycling and via this mechanism contributes to the buildup 
of corticopapillary osmotic gradient. This osmotic gradient is important drive for the water 
reabsorption in the collecting tubule. It is important to note that the AVP on top of the above 
mentioned effects in the collecting ducts, it also increases the activity of the Na+-K+-2Cl- 
cotransporter (NKCC) in the thick ascending limb of the loop of Henle, hence augmenting the 
corticopapillary osmotic gradient (Fenton and Knepper 2007).. Moreover, the AVP increases 
sodium reabsorption in the collecting duct by increasing the activity of the amiloride-sensitive 
epithelial sodium channel (ENaC) (Bankir et al. 2005). 
The constant physiological regulation greatly varies the rate of water reabsorption in the 
collecting ducts and finally 0.5-10% of the filtered water can be excreted. The rate of urine 
production is mainly regulated by water reabsorption through the aquaporin-2 channels (AQP2) 
presence and thus the water permeability in the collecting duct principal cells. The water 
permeability of the collecting ducts is AVP dependent and is under constant regulation. The 
huge variation of the water reabsorption in the collecting duct is the consequence of specific 
chain of events which modify the water permeability, the AQP2 presence in the luminal (apical) 
membrane of the collecting tubule principal cells. Under maximal AVP influence only ~0.3 ml 
fluid per minute is excreted, however in lack of AVP induced concentrating function of the 
kidneys it can raised as much as ~12 ml urine production per minute. The osmolality of urine 
changes reciprocally with the volume of urine output; the osmolality can be as high as ~1300 
mosm/kg water in maximal antidiuretic condition and as low as ~30 mosm/kg water in maximal 
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diuresis in humans. After restoration of water balance, due to the termination of AVP secretion 
from the neurohypophysis and the elimination of circulating AVP molecules by kidney and 
liver vasopressinases, the AVP level decreases in a short time (10-30 min) (Czaczkes et al. 
1964). Consequently, the V2R induced mechanisms in principal cells diminish resulting the 
relocation of AQP2 water channels into endomembrane compartments which in turn greatly 
reduces the water permeability and reabsorption capacity of the collecting duct.  Under normal 
conditions, the presence of AQP2 water channels in the luminal surface of the principal cells is 
the permissive factor for the water reabsorption. 
Impaired regulatory mechanisms in the AVP action or genetic defects in the 
participating proteins can lead to disturbed renal function and diseases such as diabetes 
insipidus (DI) or nephrogenic syndrome of inappropriate diuresis (NSIAD) depending on that 
loss-of-function or gain-of-function mutations are behind the restricted or exaggerated transport 
functions. Investigations of such disorders have contributed enormously to our understanding 
of the mechanisms of urinary concentration and identified the important proteins and revealed 
potential therapeutic interventions to cure or unburden the symptoms. 
 DI is a rare disease, the prevalence is approximately one per 30,000 and characterized 
by the inability to normally concentrate urine resulting in several symptoms such as polyuria  
(40-150 ml/kg/day, depending on the age), hyposthenuria (low specific gravity of urine, <290 
mOsm/L), and compensatory polydipsia (Robertson 1995). This disease burdens normal life 
due to production and micturition of large volumes of urine all day long. Moreover, in severe 
forms of the disorder, the individuals must micturate and drink fluid even at night a few times. 
The DI is frequently associated with urological complications such as impaired bladder 
function, hydronephrosis, chronic renal failure, and large dilations of the urinary tract (Shalev 
et al. 2004; Boyd et al. 1980). The patients can be held in water balance as long as the fluid 
intake compensates the excessive urine output. The thirst sensation and its regulation is essential 
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safety backup mechanism since the compensatory water intake reflexes can avoid the 
development of severe hyperosmolality in the blood plasma. Unfortunately, if the water intake 
is limited, the patient becomes dehydrated and hypovolumic by reason of excessive water loss.  
This chapter gives an overview of the various DI types focusing to the NDI, including 
the pathophysiology and potential therapeutic interventions in such disorders.  
 
Nephrogenic diabetes insipidus (NDI) 
In the NDI disorder, albeit the AVP production and its secretion is normally regulated 
by the hyperosmotic stimuli, the principal cells in the collecting ducts do not respond normally 
to the hormone. The irresponsiveness can be caused by several factors such as genetic defects 
(familial or congenital nephrogenic diabetes insipidus due to mutations either in the AVPR2 or 
AQP2 genes) or can be acquired i.e. from drug therapies. In adults, the acquired forms are more 
common, whereas children mostly present congenital forms of NDI (cNDI). In this chapter, we 
summarize the causes and the pathophysiological consequences of NDI, furthermore, we 
discuss the new treatment possibilities that have been proposed by the current research data in 
the literature to medicate or disburden the symptoms of NDI. The cited OMIM entries can be 
found at www.omim.org (Amberger and Hamosh 2017). 
 
Types of NDI 
Congenital forms of NDI (cNDI) 
The hereditary NDI syndromes most commonly due to the mutations either in the 
AVPR2 or in the AQP2 gene (primary NDIs). Approximately 90% of the NDI cases are related 
to the malfunction of the V2R and its signaling, and ~10% is due to the autosomal mutations in 
the AQP2 gene. Interestingly, the dysfunction of V2R or AQP2 cause indistinguishable clinical 
symptoms which are manifested immediately after birth. In top of the mutations in the AVPR2 
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or AQP2 gene, other genetic renal diseases can be in the background of the symptoms 
(secondary NDIs) (Bockenhauer and Bichet 2013). Most patients suffering from cNDI are 
diagnosed within the 3 years of life, with excessive vomiting, reduced growth, underweight, 
constipation, fever and dehydration.     
 
Disease causing mutations of V2 vasopressin receptor (OMIM 304800) 
The V2R belongs to the G protein–coupled receptor (GPCR) superfamily, composed by 
371 amino acids that forms seven transmembrane domains. In the principal cells, the V2R acts 
mostly via coupling to Gs proteins thus regulating the intracellular 3',5'-cyclic adenosine 
monophosphate (cAMP) level in target cells. Members of the GPCR superfamily are the largest 
group of cell membrane receptors and their mutations are responsible for numerous human 
diseases given the fact that more than 600 loss of function mutations of GPCR’s have been 
identified (Schoneberg et al. 2004), including the majority of congenital NDI cases (Bichet 
2009). The mutations in the V2R can cause failure in urine concentration due to several 
mechanisms including the inability to establish the corticopapillary osmotic gradient and the 
impaired water transport through collecting duct principal cells but the most palpable 
dysfunction that defective V2R function in the principal cells induces hyposmotic polyuria 
production. Under normal circumstances in healthy individuals, the AVP stimulation induced 
V2R activation triggers cAMP signaling cascades, most importantly the activation of protein 
kinase A (PKA) which in turn phosphorylates the AQP2 on several residues that triggers the 
vesicular transport of AQP2 containing endomembranes into the apical membrane allowing 
water reabsorption in the collecting ducts (Figure 1A) (Nielsen et al. 2002). Once the AVP 
secretion is diminished in response to the restored water balance, AQP2 abundance is also 
reduced due to its internalization through ubiquitin-mediated endocytosis and transport to 
storage vesicles and degradation (Kamsteeg et al. 2006). This regulation of AQP2 water channel 
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localization is crucial to increase urine osmolality and to reduce urine output in humans 
(Moeller et al. 2013). In addition to the classical PKA activation pathway, it is important to 
emphasize that the increased intracellular cAMP directly binds and activates other effector 
signaling protein such as Epac (exchange factor directly activated by cAMP) which functions 
as guanine-nucleotide exchange factor for the small GTPase. It was demonstrated that the AQP2 
abundance on the luminal surface of the principal cells mainly depends on the Epac activation 
and was independent on the PKA activity (Kortenoeven et al. 2012). Interestingly, during the 
aforementioned signaling processes, the AVP-bound V2R active receptor conformation is 
phosphorylated by GRK molecules which leads to recognition and association with β-arrestin 
molecules and the receptor is desensitized (although the AVP is still bound to the receptor). 
The arrestin recruitment initiates several important regulatory mechanisms. First, the arrestin 
molecules as scaffold proteins to organize the endocytosis of the V2R which results in the 
decreased cell surface receptor density and the degradation of the receptor in the lysosomes (the 
AVP is bound so tightly that it can be dissociated from the receptor only upon break-down of 
the receptor molecule). The β-arrestin mediated receptor down-regulation prevents from 
exaggerated reabsorption in the collecting ducts and allows the possibility to regulate smoothly 
and rapidly the rate of water reabsorption.  
AVP induced V2R activation is necessary not just for the normal AQP2 trafficking 
pattern but also required for the normal AQP2 expression levels. It was demonstrated that 
although the intracellular cAMP level decays shortly after AVP stimulation, the AQP2 
expression remains increased for days (DiGiovanni et al. 1994; Kortenoeven et al. 2012). 
Interestingly, the upregulatory effect of AVP on the AQP2 expression level was dependent on 
extracellular signal-regulated kinase (ERK), Epac activation and cAMP response element-
binding protein (CREB) but not on PKA activity (Umenishi et al. 2006; Kortenoeven et al. 
2012). In addition to the above mentioned effects, the V2R normally contributes to the buildup 
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of corticopapillary interstitial osmotic gradient as its function is required for the normal 
expression and function of urea transporters in the collecting duct and Na+-K+-2Cl- 
cotransporter in the thick ascending limb of the loop of Henle (Fenton and Knepper 2007). 
Moreover, the AVP increases sodium reabsorption in the collecting duct by increasing the 
activity of the amiloride-sensitive epithelial sodium channel (ENaC) (Bankir et al. 2005). 
Several mutations have been identified causing congenital nephrogenic diabetes 
insipidus (cNDI) (Barak et al. 2001; Tao 2006; Wilbanks et al. 2002). The cNDI is a rare disease 
and it is caused due to the mutations in either AVPR2 or AQP2 gene. Among the cNDI cases 
approximately 90% of the patients are males with the X-linked recessive mutation in the AVPR2 
gene resulting defective V2R in the kidney epithelial cells (Bichet 2009). The prevalence of 
this form (also called as type I cNDI or as XNDI) is ~1 in 150,000 male births although mild 
forms of X-linked cNDI can be present in females, as well. The AVPR2 gene is located on 
chromosome region Xq28, which contains three exons and two introns and after shortly its 
cloning it was proposed that it could be responsible for congenital NDI (Seibold et al. 1993; 
Rosenthal et al. 1992; Birnbaumer et al. 1992). It was also demonstrated in early works that the 
patients with cNDI does not respond to desmopressin (dDAVP) treatment suggesting that the 
cAMP signaling is defective in these cases (Bichet et al. 1989; Bichet et al. 1988). 
As it was mentioned above, few cNDI families were described in the literature, in which 
the female family members exhibit variable degrees but usually mild symptoms of diabetes 
insipidus (Carroll et al. 2006; van Lieburg et al. 1999; Nomura et al. 1997). These heterozygous 
female individuals possess both normal and mutated AVPR2 alleles. The studies on the skewed 
X-chromosome inactivation patterns of the female members suggested that the severity of 
symptoms were dependent on the rate of skewed methylation of X chromosome, and the NDI 
phenotype is caused by dominant methylation of the normal allele of AVPR2 gene (Nomura et 
al. 1997; Arthus et al. 2000). 
11 
 
The NDI causing various mutations in V2R evolve their dysfunctions with different 
mechanisms (Arthus et al. 2000; Tao 2006). More than 260 mutations are described in the 
Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AVPR2), 
majority of them are missense mutations (~61%), which act by different mechanisms (Spanakis 
et al. 2008). In addition, approximately 25% of the mutations are frameshift mutations due to 
nucleotide deletions or insertions, ~10% is non-sense mutations, and ~9% of the cases are large 
deletions, but infrequently complex rearrangements, splicing mutations, in-frame deletions or 
insertions are also responsible for the X-linked NDI disorders (Bichet and Bockenhauer 2016). 
The V2R is composed by 371 amino acids that forms several domains and mutations have been 
identified all over in the receptor but the most of the mutations are found in the transmembrane 
domains. The most frequent mutations are recurrent mutations which have been identified in 
35 ancestrally independent families and mostly these occurred at potential mutational hot spots 
(a C-to-T or G-to-A nucleotide substitution occurred at a CpG dinucleotide) (Bichet and 
Bockenhauer 2016).  
The mutation also can be classed by the nature of the impaired vasopressin receptor 
function. The classical classification of the mutations causing impaired V2R function is based 
on the pathophysiological and cellular consequences (Wesche et al. 2012). The AVP 
insensitivity can be the consequence of either decreased number of cell surface receptors or 
impaired receptor signal transduction (Figure 1B). Class I mutations of the AVPR2 gene can 
lead to impaired transcription, mRNA processing or translation of the receptor resulting 
truncated and usually rapidly degraded proteins. Taken together, the class I mutations prevent 
effective synthesis of the V2R. Class II mutations lead to the formation of misfolded full length 
proteins, which are recognized by the quality control system of the endoplasmic reticulum (ER), 
resulting defective intracellular trafficking of the V2R mutants, ER retention and often 
degradation of the trapped receptors (Robben et al. 2006). In fact, the majority of AVPR2 gene 
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mutations are missense/nonsense mutations which result class II mutant receptors. Class III 
mutants are another group of missense mutations, which reach the basolateral plasma 
membrane but they display reduced G protein binding and/or G protein activation ability in 
response to AVP stimulation (class IIIa subtype) or their AVP binding is defective due to their 
impaired ligand affinity (class IIIb subtype), leading to inappropriate intracellular cAMP 
production and AQP2 trafficking. Class IV mutants have normal ligand binding but their 
intracellular trafficking is altered causing impaired cAMP signal production mostly due to 
constitutive β-arrestin dependent internalization even in absence of ligands leading to decreased 
basolateral surface expression since the V2R accumulation in intracellular vesicles (Barak et 
al. 2001).  
To complicate the picture further, the evaluation of the properties of a mutant V2R does 
not always lead to an unambiguous classification of the mutation. For example, the NDI causing 
R137H-V2R was classified as class IV mutation due to its constitutive β-arrestin dependent 
internalization (Barak et al. 2001). Moreover, the R137H-V2R has also impaired G-protein 
coupling (Rosenthal et al. 1993) and altered trafficking to the plasma membrane as well (Kocan 
et al. 2009). Interestingly, contrary to the symptoms of R137H, the R137C-V2R and R137L-
V2R mutations lead to nephrogenic syndrome of inappropriate dieresis (NSIAD) due to the 
constitutive activity.  
 
Gain-of function V2R mutations cause nephrogenic syndrome of inappropriate 
diuresis (NSIAD) (OMIM 300539) 
Whereas the loss-of-function V2R mutations are responsible for the majority of the 
cNDI disorders, the gain-of-function mutations in the V2R lead to nephrogenic syndrome of 
inappropriate antidiuresis disease (NSIAD). This recently discovered syndrome may cause 
hyponatremia and especially in infants severe clinical symptoms such as convulsions. NSIAD 
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is a very rare, X-linked disorder with monogenic inheritance, and to date, mutations of Phe229, 
Arg137, Ile130 and Leu312 have been identified as gain-of-function mutations in V2R 
(Carpentier et al. 2012; Erdelyi et al. 2015; Feldman et al. 2005; Tiulpakov et al. 2016). The 
clinical manifestation of NSIAD such as hyponatremia and reduced urinary dilution is 
undistinguishable from the SIADH but very markedly the serum AVP level is low in NSIAD 
whereas it is elevated in SIADH (Decaux et al. 2007). It was demonstrated that NSIAD causing 
gain-of-function mutation can lead to selective G-protein activation and increased secondary 
messenger production in the cells. The increased activity of V2R can be blocked by an V2R 
inverse agonist tolvaptan which could be a possible treatment option for the patients with this 
type V2R mutation (Erdelyi et al. 2015). 
 
Congenital NDIs due to mutated AQP2 (OMIM 125800) 
In the other main form of cNDI which corresponds approximately ~10% of the inherited 
NDI cases, the patients suffers from autosomal mutation in the gene encoding the AQP2 water 
channel (Bichet 2009). The patients exhibit typical features of NDI similarly to V2R loss-in-
function mutations caused symptoms, the disorder is vasopressin resistant, but it is associated 
with nonfunctional water channels. This form of hereditary NDI is also called as type II form 
of cNDI, and the characteristic difference from the type I form is that the intracellular cAMP 
level increases in response to AVP stimulation (Zimmerman and Green 1975; Deen et al. 1994; 
Langley et al. 1991). The autosomal cNDI can be caused by heterozygous, homozygous, or 
compound heterozygous mutation in the AQP2 gene, and both autosomal-recessive or 
autosomal-dominant mode of inheritance are described (Morello and Bichet 2001; van Lieburg 
et al. 1999; Deen et al. 1994). The chromosomal location of AQP2 is 12q12-q13 and to date 61 
mutations have been identified (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AQP2) (Bichet 
and Bockenhauer 2016). The majority of the mutations (48) are missense/nonsense mutations, 
14 
 
but few splicing, small deletion and insertion mutations are also presented in the databases. The 
consequences of AQP2 gene mutations can be different depending the nature of the mutation 
but most commonly result in impaired vesicular transport of AQP2 water channels. Under such 
condition the AQP2 molecules are retained in the endosomes and not translocated into the apical 
(luminal) surface of the principal cells (Tamarappoo and Verkman 1998). As it was discussed 
in case of the misfolded and misrouted V2R mutant proteins, theoretically, it is possible to 
intervene by the help of pharmacological chaperones which could facilitate the reverse of the 
intracellular retention of AQP2 mutant proteins. Most of the mutations are autosomal recessive 
mutations leading to misfolding, ER retention, and degradation of the produced AQP2 mutants 
(Moeller et al. 2013; Wesche et al. 2012; Frick et al. 2014). Although, the majority of the 
dominant mutations result in complete lack of functionality, some ER-retention mutants, in 
which the misfolding is not severe, display reduced degradation and partial responsiveness to 
AVP stimulation (Canfield et al. 1997; Frick et al. 2014; Marr et al. 2001; Marr et al. 2002; 
Mulders et al. 1997). Interestingly, these dominant mutations cause less severe phenotype 
compared to patients with compound heterozygous or homozygous for recessive mutations 
(Mulders et al. 1998; Bichet and Bockenhauer 2016). The dominant mutations affect the 
carboxyl terminus of AQP2, their folding is correct and they are not retained in the ER, although 
due to the mutations they are not able to cooperate fully with the wild type AQP2 molecules. It 
was demonstrated that such mutants form mixed tetramer complex with the wild type AQP2 
but they are misrouted and retained in the Golgi compartment (Mulders et al. 1998; de Mattia 
et al. 2004; Kamsteeg et al. 1999).  
 
“Complex” NDI 
The AVPR2 or AQP2 gene mutations caused symptoms are also called as “pure” NDI 
phenotypes since they display water loss but the electrolytes such as sodium, potassium, 
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chloride and calcium are normally conserved (Bockenhauer and Bichet 2017). The “complex” 
NDI can be caused by mutant membrane proteins involved in sodium chloride reabsorption in 
the thick ascending limb of the loop of Henle leading to not just loss of water but also electrolyte 
loss. Such mutations can be found in the genes encoding the Na+-K+-2Cl- cotransporter, renal 
outer medullary potassium channel (ROMK), Barttin (Bartter syndrome, infantile, with 
sensorineural deafness), kidney-specific chloride channel ClC-Kb and chloride channel Ka 
causing polyuria, polydipsia and loss of sodium, chloride, calcium, magnesium and potassium 
(Bockenhauer and Bichet 2017). 
 
Acquired forms of NDI 
The majority of the NDI cases are acquired diseases caused be various factors including 
complications of drug treatments, pathophysiological alterations such as electrolyte 
disturbances including hypokalemia and hypercalcemia, and diseases (sickle cell disease, 
sarcoidosis, amyloidosis, multiple myeloma, Sjoergen's disease). Numerous data have been 
reported that NDI can be induced by various other drugs and medicine including lithium, 
demeclocycline, foscarnet, clozapine, cisplatin or methoxyflurane (Bendz and Aurell 1999). 
Consumption and uptake of trace amounts of lithium is essential for the normal brain, 
immune and reproductive functions, and it is well known that lithium deficiency leads to serious 
health problems, including behavioral problems. The lithium treatment is still the most effective 
cure in bipolar disorders and has been used for decades despite the disadvantages such as renal 
side effects. The lithium caused DI is a serious, well-studied side effect in the treatment of 
bipolar mood disorders leading to polyuria (and consequent dehydration, thirst, and polydipsia), 
elevated renal sodium excretion and even chronic kidney disease (Nielsen et al. 2008). The 
lithium treatment induces vasopressin-resistant polyuria in 20-40% of the patients mostly due 
to the disruption of normal aquaporin function and increased sodium excretion as the result of 
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epithelial sodium channel (ENaC) dysfunction in the kidney collecting ducts (Marples et al. 
1995). The renal lithium handling is similar of the sodium due to their similar size and charge. 
The lithium enters the distal tubule segments through the amiloride-sensitive ENaC in the distal 
tubule segments and leaves the cells via Na+/H+ exchanger, NHE1 to the interstitium. It is 
demonstrated that clinically relevant lithium concentrations reduced the mRNA transcription 
and protein expression of AQP2 which can be reversed by administration of amiloride, 
moreover the lithium treatment disrupted the normal trafficking and distribution pattern of 
AQP2 (Kortenoeven et al. 2009; Li et al. 2006). In addition to the reduced AQP2 level in the 
apical surface the transcellular water transport is greatly diminished by the fact that lithium 
decreases the expression of the basolaterally located AQP3 level too in the collecting duct 
principal cells (Kwon et al. 2000). Chronic lithium treatment has been reported to inhibit the 
sodium transport through the amiloride-sensitive ENaC resulting in increased sodium excretion 
(Thomsen et al. 1999). Furthermore, it has been demonstrated that other sodium transport 
functions are also affected in response to lithium treatment. The distal convoluted tubule located 
thiazide-sensitive Na-Cl cotransporter (NCC), the proximal tubule located the type 2 sodium-
phosphate cotransporter (NaPi-2) and electrogenic sodium-bicarbonate cotransporter (NBC1) 
are down-regulated during lithium treatment (Kwon et al. 2000). The lithium also reduces the 
water reabsorption ability by affecting the urea cycling that normally contributes to the buildup 
of corticopapillary interstitial osmotic gradient. It has been demonstrated that chronic lithium 
treatment induces decreased urea transporter abundance (Klein et al. 2002). Taken together, on 
top of the dysfunctional AQP2, sodium wasting due to the impaired sodium cotransporter 
factions and due to the reduced urine concentrating ability due to the urea transporter deficiency 
also play important role in the development of polyuria during chronic lithium treatment. The 
symptoms of the lithium-induced side effects can be alleviated by administration of thiazide 
and amiloride (Bedford et al. 2008a), angiotensin-converting enzyme inhibitors, AT1R 
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angiotensin II receptor blockers, or spironolactone mineralocorticoid receptor blocker (Kwon 
et al. 2009).   
Demeclocycline is tetracycline derivative antibiotic, indicated for the treatment of 
various types of bacterial infections. It has been demonstrated that chronic demeclocycline 
treatment has several side effects including set up of NDI (Singer and Rotenberg 1973). It was 
revealed that demeclocycline-induced NDI is the consequence of the decreased AQP2 
expression and its cell surface abundance in response to the treatment (Kortenoeven et al. 2013). 
Interestingly, demeclocycline reduced the adenylate cyclase activity in kidney cells and its 
effect was independent on V2R signaling. The demeclocycline is not really used in the 
treatment of infections nowadays, but its renal side effects were utilized to alleviate the 
symptoms of syndrome of inappropriate antidiuretic hormone (SIADH). In SIADH the 
neurohypophysis secretes abnormally high levels of AVP, which in turn results in excessive 
water reabsorption in the collecting ducts. The too high level of water retention causes volume 
expansion in the fluid compartments whereas the osmolality of the extracellular and 
intracellular fluids become decreased compared with the normal levels. Moreover, the high 
level of AVP increases the Na+-reabsorption through NKCC cotransporter and epithelial 
sodium channel (ENaC) (Ecelbarger et al. 2001). The use of demeclocycline in SIADH is based 
on the fact that the drug reduces the AVP-evoked hyponatremia, although the development of 
V2 vasopressin receptor antagonists, the vaptans, supersedes its usage in the treatment of 
SIADH (Sherlock and Thompson 2010). 
 
Treatment possibilities for NDI 
In contrary to central DI where the desmopressin is widely and successfully used to 
mend the symptoms, the treatment of NDI patients is more difficult to achieve. In the past, 
several potential treatment possibilities of DI were described (reviewed recently by (Kalra et 
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al. 2016)) such as the usage of carbamazepine (Rado 1976; Meinders et al. 1974), 
clorpropamide (Wales and Fraser 1971), thiazide diuretics (Alon and Chan 1985; O'Doherty et 
al. 1962), amiloride (Bedford et al. 2008b; Kortenoeven et al. 2009), indapamide (Kocak et al. 
1990), clofibrate (Moses et al. 1973), indomethacin (Weinstock and Moses 1990). The 
treatment of cNDI was tuned during the years. The combination of amiloride and 
hydrochlorothiazide was found superior than the combination of hydrochlorothiazide and a 
prostaglandin synthetase inhibitor (Alon and Chan 1985). The inhibitors of prostaglandin 
synthesis are also useful medicines to ameliorate the symptoms of cNDI, and among the tested 
inhibitors, the indomethacin was much more effective than ibuprofen (Libber et al. 1986). In 
addition to these drugs, the recent findings have suggested novel therapeutic possibilities.  
The identification of the NDI causing mutations and the determination of the altered 
properties and cellular consequences altered could help to define or suggest therapeutic 
strategies for the treatment of NDI patients. The potential therapeutic approaches deal with 
either bypassing the V2R signal transduction processes or the improve of AQP2 function. It is 
proposed and highly recommended to identify the potential genetic defect as soon as possible 
in case of chance of congenital NDI. Both AVPR2 and AQP2 genes can be sequenced with ease 
due to their relatively small size. The genetic testing of infants whose families may be 
associated with congenital NDI can be performed even prenatal or perinatal periods from 
amniotic cells, chorionic villous samples or cord blood (Bichet and Bockenhauer 2016). Since 
the inherited NDI is manifested immediately after birth, it is fundamental to correctly recognize 
the disorder, and especially in case of infants, it is essential to treat the affected individuals with 
abundant fluid intake in order to avoid the repeated episodes of dehydration since these episodes 
are probably responsible for the generation of mental and physical retardation.  
Possible interventions include direct stimulation of cAMP signal generation in the 
principal cells, bypassing the necessity of vasopressin activation, and different strategies to 
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rescue the impaired receptor function (Wesche et al. 2012). The most extensively investigated 
V2R mutants belong to the class II mutations, which cause ER retention. The ER has a quality-
control system that prevents misfolded proteins to reach their final subcellular destinations 
(Ellgaard and Helenius 2003). Pharmacological chaperons or pharmacochaperons are small, 
cell permeable substances that meliorate the folding of misfolded mutated, otherwise functional 
proteins in the ER. By the result of pharmacochaperon action the misfolded proteins can bypass 
the ER quality-control system and rescue them from ER retention. This phenomenon proposed 
a therapeutic approach in which the chaperons can lead to increased plasma membrane 
expression of otherwise functional vasopressin receptor mutants. Numerous data have been 
presented the usage of pharmacological chaperons to mend the dysfunctional V2R mutants. 
Pharmacological chaperones of the V2R can be antagonists (Bernier et al. 2004; Morello et al. 
2000; Ranadive et al. 2009; Robben et al. 2007; Wuller et al. 2004) or agonists (Jean-Alphonse 
et al. 2009; Robben et al. 2009). The approach was also confirmed in clinical studies of X-
linked NDI patients who suffer from ER retention V2R mutations. Administration of SR49059 
V1a receptor nonpeptide antagonist significantly reduced the urine volume and water intake, 
and increased the urine osmolarity suggesting the pharmacochaperons may offer a new 
therapeutic approach to the treatment of the NDI patients who suffer from ER retention mutant 
V2R mutations. (Bernier et al. 2006).  
The altered mutant V2 receptor conformations can result decreased potency for AVP 
and other ligands such as dDAVP. Theoretically the potency of other agonists can be affected 
differently and certain agonists may activate the mutant receptor despite of the conformational 
change. Screening and testing drug libraries can yield ligands which can be personal therapy in 
case of a certain mutation. In case of N321K-V2R mutation, which caused a conformation with 
altered agonist sensitivity, the mutant receptor can be stimulated and activated by dVDAVP 
proposing a therapeutic for patients with N321K mutation in the V2R (Erdelyi et al. 2014). 
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Taken together, the promising recent and future experimental data may provide personalized 
medicine that is specific for the individual patients with a certain mutations causing NDI.   
 It is also promising that some interventions may bypass the V2R activation in order to 
generate cAMP signal for the PKA mediated APQ2 translocation, thus urinary concentration 
can be independent of V2R. In the collecting duct, locally produced autocrine and paracrine 
factors including bradykinin, ATP, adenosine, endothelin, nitric oxide, and prostaglandin E2 
(PGE2) may also regulate the water permeability (Pearce et al. 2015; Sands and Layton 2014). 
It was demonstrated that PGE2 receptor EP4 activation promotes AQP2 translocation via cAMP 
signal and PKA activation, moreover it also induces AQP2 expression in a cAMP response 
element-binding protein (CREB)-dependent manner (Gao et al. 2015). This finding makes the 
EP4 receptor agonists as potential therapeutic drugs for the treatment of DI, irrespectively of 
the type of the DI. It was also demonstrated that the agonist stimulation (pro)renin receptor, 
which is also expressed in the collecting duct and it is regulated by the PGE2 receptor EP4, 
induced AQP2 expression, whereas its inhibition  partially prevented the decrease in urine 
volume and the increase in urine osmolality and AQP2 expression induced water deprivation 
in in vivo animal studies (Wang et al. 2016). It was discovered recently adenosine 
monophosphate kinase (AMPK) is capable to phosphorylate both AQP2 and urea transporter 
UT-A1 in rat inner medullary collecting ducts in response to metformin stimulation (Klein et 
al. 2016). The authors used metformin as AMPK activator, which is approved to use in patients 
with type 2 diabetes mellitus and polycystic ovary syndrome. The metformin increased the 
apical membrane expression of AQP2, both osmotic water permeability and urea permeability 
in collecting ducts. Erlotinib, which is a receptor tyrosine kinase inhibitor selective for 
epidermal growth factor receptor (EGFR), is a medication in the treatment of some cancer 
including non-small cell lung cancer, pancreatic cancer. It is currently identified in a high–
throughput chemical screening assay that erlotinib was effective to stimulate AQP2 
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translocation and reduced urine output 45% in lithium-induced NDI model in cAMP-
independent manner (Cheung et al. 2016). Since animal studies suggest metformin and erlotinib 
as novel therapeutic options for NDI and  given the fact that both are approved medications, it 
was suggested to initiate clinical trials to determine the benefits of these drugs in the treatment 
of various forms of diabetes insipidus (Bockenhauer and Bichet 2017; Bech et al. 2018). It was 
demonstrated that activation of cGMP-mediated signaling pathway could result in AQP2 
translocation and administration of cGMP phosphodiesterase type 5 inhibitor sildenafil 
significantly increased the AQP2 insertion into the luminal membrane compartments. Sildenafil 
induced elevated intracellular cGMP levels and the plasma membrane accumulation of AQP2 
was not dependent on V2R activation (Bouley et al. 2005). Other possibility to bypass the V2R 
induced AQP2 translocation is the stimulation of β3 adrenergic receptor. The β3 adrenergic 
receptor is also expressed in the collecting duct and it was demonstrated that its stimulation 
with the selective agonist BRL37344 induced cAMP signal and translocation of AQP2 in the 
principal cells, and also increased the activity of Na+-K+-2Cl- cotransporter in the thick 
ascending limb of the loop of Henle. Taken together, administration of BRL37344 promoted a 
potent antidiuretic effect in AVPR2-deficient animals (Procino et al. 2016). Since the 
mirabegron, a β3 adrenergic receptor is already introduced in the clinical practice to treat 
overactive bladder, enticing possibility to carry out clinical investigations to test the potential 
ameliorating effects of this drug in NDI patients (Cernecka et al. 2014; Chapple et al. 2014). 
The other possible therapeutic option can be the administration of simvastatin, a lipid-lowering 
medication since it was recently demonstrated that it was able to reduce urine output and 
increase urine osmolality in hypercholesterolemic patients (Procino et al. 2016). A recent 
clinical study investigated the effects of sildenafil, metformin, and simvastatin on AVP-
independent urine concentration in healthy volunteers, and only simvastatin had an effect on 
urine osmolality in healthy volunteers, although further studies are necessary to address the 
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possible effects of these drugs in combination or in patients suffering from NDI (Bech et al. 
2018). 
 
Other major types of and differential diagnosis of diabetes insipidus 
Early diagnosis and correct typing of the DI is critical, especially in infants and small 
children since the consecutive, repetitive dehydration episodes can lead to mental and physical 
retardation (Bichet 2009). The symptoms of untreated DI eventually may lead to death due to 
exsiccosis, electrolyte imbalances, hyperosmolality, and low blood volume caused circulatory 
failure. The clinical diagnosis of the DI is based on functional tests. The widely used tests are 
the water deprivation test and administration of the dDAVP (desmopressin) to distinguish 
between the various forms of DI (Di Iorgi et al. 2012). 
The DI can be inherited (less than 10% of the cases) or acquired (Fujiwara and Bichet 
2005). The symptoms of DI can be the consequence of four fundamentally different reasons 
which are used for the classification the various forms of DI (Fenske and Allolio 2012). In the 
clinical practice, it is essential to diagnose the type of the syndrome for the proper treatment of 
the individual, especially in less severe forms of the symptoms (Robertson 1988).  
The central DI (CDI) (OMIM 125700) is due to the impaired AVP production or release 
from the central nervous system and can be acquired or congenital and the syndromes are the 
consequence of deficient release of AVP from the neurohypophysis (Arima et al. 2016). The 
prevalence of CDI is about 1:25000, and in children, CDI is more frequent than the NDI mostly 
due to brain injuries. The CDI can be treated by using an analogue of vasopressin, the V2R 
selective agonist desmopressin (1-deamino-8-D-arginine vasopressin, ddAVP) that has several 
benefits over administration of AVP due to the lack of vascular side effects and longer half-life. 
The desmopressin is now available not only as nasal spray but also as oral tablet (even in 
sublingual form) to ease the way of administration. Interestingly, dissimilarly to CDI, in the 
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syndrome of inappropriate antidiuretic hormone (SIADH) the neurohypophysis secretes 
abnormally high levels of AVP, which in turn results in excessive water reabsorption in the 
collecting ducts. The too high level of water retention causes volume expansion in the fluid 
compartments and hyponatremia whereas the osmolality of the extracellular and intracellular 
fluids become decreased compared with the normal levels (Wakil et al. 2011). 
The gestational DI is a rare complication, the prevalence is approximately one per 
30,000 pregnancies (Fenske and Allolio 2012). This form of the DI is the consequence of the 
rapid elimination (metabolism) of the circulating AVP by the placental vasopressinase, also 
called placental cysteine aminopeptidase, secreted by the trophoblasts. In rare occasions, the 
disorder can be due to exaggeration of pre-existing mild forms of CDI or NDI. The symptoms 
usually manifest in the third trimester of pregnancy, especially carrying multiple fetuses 
(Ichaliotis and Lambrinopoulos 1965). The rapid elimination of the circulating AVP causes 
transient DI and usually can be treated by the administration of desmopressin which is resistant 
to vasopressinase cleveage (Ananthakrishnan 2016). The transient GDI is usually resolved after 
delivery (within few weeks), although in subsequent pregnancies can cause even severe 
symptoms (Kalelioglu et al. 2007).   
The dipsogenic or psychogenic DI can be caused by primary polydipsia which is 
excessive water intake due to impaired thirst perception (dipsogenic DI) or psychological 
function (psychogenic DI). Primary polydipsia can be induced by either defective thirst 
sensation or perception and frequently is associated with schizophrenia, anxiety disorder and 
depression, although an increasing number of cases demonstrate primary polydipsia in non-






Early detection and providing abundant water supply or treatment for DI patients is 
essential to allow normal mental and physical development, normal lifespan (Bichet and 
Bockenhauer 2016). In case of infants and small children and it is highly recommended to 
sequence of their DNAs to obtain correct diagnosis if  hypernatremic dehydration episodes 
occur (Bockenhauer and Bichet 2017). Since both AVPR2 and AQP2 are small genes, their 
sequence can be easily sequenced, allowing not just perinatal and prenatal testing but the 
genetic testing of the carriers, as well (Bichet and Bockenhauer 2016). 
 
Conclusion 
 Diabetes insipidus is a rare disorder with diversity of backgrounds which impairments 
affect either the V2 vasopressin receptor or the AQP2 water channel functions. It is essential to 
keep the patients in water balance either by the treatment of the disease (i.e. in case of central 
DI) or by providing necessary amount of fluid intake. It is also pivotal to identify the nature of 
the disorder as early as possible to reveal the cause behind the disorder and to treat the patient 
appropriately. Although numerous potential new treatment possibilities proposed currently, 
more translational research is necessary to offer personalized medicine for the patients who 






Figure 1: Schematic illustration of AVP-induced AQP2 insertion into the apical surface 
of collecting duct principal cells (A) and the possible causes behind the development of 
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NDI (B). Under normal circumstances (A), the AVP travels via bloodstream to the kidneys 
where it binds to the basolaterally located V2R. This receptor is a G protein–coupled receptor 
and initiates cAMP signaling within the principal cells. The activation of PKA induces the 
vesicular trafficking of AQP2 containing endomembranes. Finally, the AQP2 is translocated 
into the apical surface making this water permeable, and the water molecules are transported 
from the duct lumen to the kidney interstitium via the apically located AQP2 and the 
permanently located basolateral AQP3 and AQP4 water channels. (B) In cNDI, the impaired 
water transport is the consequence of mutations in the AVPR2 or AQP2 (labeled with roman 
numerals). Class I type of mutations can lead to impaired transcription, mRNA processing or 
translation, class II mutations lead to endoplasmic reticulum (ER) retention, class IIIa mutants 
display reduced G protein binding and/or G protein activation whereas class IIIb mutations 
cause impaired ligand affinity, class IV mutants display altered intracellular trafficking leading 
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